SYRE Q2 2018 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+60.8% YoY

Gross Profit

$00.0% margin

Operating Income

-$10M-406.6% margin

Net Income

-$9M-395.9% margin

EPS (Diluted)

$-11.43

QoQ Revenue Growth

+57.5%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$996,000

Balance Sheet

Total Assets

$80M

Total Liabilities

$6M

Stockholders' Equity

$73M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$1M	+60.8%
Gross Profit	$0	$0	—
Operating Income	-$10M	-$7M	-43.9%
Net Income	-$9M	-$7M	-41.9%